Meena Indrakanti

Company: Stoke Therapeutics

Job title: Senior Vice President, Translational DMPK and Clinical Pharmacology

Bio:

Meena is the Senior Vice President of Translational DMPK and Clinical Pharmacology at Stoke Therapeutics. Prior to joining Stoke in 2018, Meena served as senior director of bioanalytical, pharmacology and biomarker development at Wave Life Sciences. She played a pivotal role in building Wave’s stereopure oligonucleotide chemistry platform and in guiding the clinical entry of three antisense oligonucleotide programs. Earlier in her career, Meena worked at Alnylam Pharmaceuticals on siRNA chemistry and targeted siRNA delivery. Meena received her Ph.D. in chemistry with Dr. K.N. Ganesh at the National Chemical Laboratory in Pune, India, and did her postdoctoral research on nucleic acid analogs with Professor Larry W. McLaughlin at Boston College.

Seminars:

Utilization of Oligonucleotides’ Half-Life to Optimize Dosing Regiment for Desirable Efficacy & Reduced CNS Toxicity 2:00 pm

Explore how chemical modifications and structural engineering can make oligos more resistant to nuclease degradation Understand the impact of half-life extension on dosing frequency, therapeutic window, and patient compliance Learn how conjugation to long-circulating carriers like antibodies can enhance PK/PD profiles and tissue retentionRead more

day: Conference Day One